Maarten J. Postma

143.7k total citations · 2 hit papers
785 papers, 12.6k citations indexed

About

Maarten J. Postma is a scholar working on Epidemiology, Economics and Econometrics and Infectious Diseases. According to data from OpenAlex, Maarten J. Postma has authored 785 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Epidemiology, 225 papers in Economics and Econometrics and 118 papers in Infectious Diseases. Recurrent topics in Maarten J. Postma's work include Health Systems, Economic Evaluations, Quality of Life (182 papers), Vaccine Coverage and Hesitancy (100 papers) and Influenza Virus Research Studies (80 papers). Maarten J. Postma is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (182 papers), Vaccine Coverage and Hesitancy (100 papers) and Influenza Virus Research Studies (80 papers). Maarten J. Postma collaborates with scholars based in Netherlands, Indonesia and United Kingdom. Maarten J. Postma's co-authors include Mark H. Rozenbaum, Stefan Vegter, Job F. M. van Boven, Cornelis Boersma, Eelko Hak, Mirjam Kretzschmar, Marinus van Hulst, Jan Wilschut, R Welte and J. C. Jager and has published in prestigious journals such as New England Journal of Medicine, The Journal of Chemical Physics and Journal of Clinical Oncology.

In The Last Decade

Maarten J. Postma

727 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

2020 218 citations Maarten J. Postma et al. profile →

Peers

Countries citing papers authored by Maarten J. Postma

Since Specialization

Citations

This map shows the geographic impact of Maarten J. Postma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten J. Postma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten J. Postma more than expected).

Fields of papers citing papers by Maarten J. Postma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maarten J. Postma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten J. Postma. The network helps show where Maarten J. Postma may publish in the future.

Co-authorship network of co-authors of Maarten J. Postma

This figure shows the co-authorship network connecting the top 25 collaborators of Maarten J. Postma. A scholar is included among the top collaborators of Maarten J. Postma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maarten J. Postma. Maarten J. Postma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health-related quality of life and disease activity in rheumatoid arthritis: a cross-sectional study in West Java, Indonesia 2025 ·Frontiers in Medicine ·(unknown), ‎Rano K. Sinuraya, (unknown), Melisa Intan Barliana, Maarten J. Postma, Auliya A. Suwantika	0
2	Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection 2025 ·PharmacoEconomics ·(unknown), (unknown), Alexia Kieffer, Maarten J. Postma, Cornelis Boersma	2
3	Clinical outcomes of chikungunya across age groups: A systematic review 2025 ·PLoS neglected tropical diseases ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Maarten J. Postma	0
4	Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations 2024 ·Vaccine ·(unknown), (unknown), Maarten J. Postma, Cornelis Boersma	5
5	Societal costs of sepsis in the Netherlands 2024 ·Critical Care ·(unknown), Elisabeth C. van der Slikke, Arthur R. H. van Zanten, Jan C. ter Maaten, Maarten J. Postma, Henk Hilderink, Robert H. Henning, Hjalmar R. Bouma	9
6	Economic burden of pelvic sepsis after anastomotic leakage following rectal cancer surgery: A retrospective cost‐of‐illness analysis 2024 ·Colorectal Disease ·(unknown), (unknown), Sarah Sharabiany, Maarten J. Postma, Pieter J. Tanis, Wytze Laméris, Roel Hompes	2
7	Knowledge on hypertension in Myanmar: levels and groups at risk 2023 ·SHILAP Revista de lepidopterología ·(unknown), Robert Lensink, Maarten J. Postma, Hla Hla Win, (unknown), Claire Stein, (unknown), (unknown), Jaap Koot, (unknown), Sijmen A. Reijneveld	1
8	Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes 2023 ·Journal of Medical Economics ·(unknown), (unknown), David Baldwin, Harry J.M. Groen, (unknown), James Ryan, (unknown), (unknown), Matthijs Oudkerk, Maarten J. Postma	8
9	Creating an evidence-based economic model for prefilled parenteral medication delivery in the hospital setting 2023 ·European Journal of Hospital Pharmacy ·(unknown), (unknown), (unknown), (unknown), (unknown), Betsy J. Lahue, (unknown), Maarten J. Postma	2
10	Parents&rsquo; Knowledge, Attitude, and Practice on Childhood Vaccination During the COVID-19 Pandemic in Indonesia 2022 ·Dove Medical Press (Taylor and Francis Group) ·‎Rano K. Sinuraya, (unknown), (unknown), Maarten J. Postma, Auliya A. Suwantika	20
11	The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance 2022 ·PharmacoEconomics ·(unknown), Daniëlle Jansen, (unknown), Christopher Butler, Theo Verheij, Alex W. Friedrich, Maarten J. Postma, Antoinette D. I. van Asselt	5
12	Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting 2021 ·Applied Health Economics and Health Policy ·(unknown), Carla Mamolo, J.C. Cappelleri, Maarten J. Postma, Bart Heeg	3
13	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI breakdown → 2019 ·New England Journal of Medicine ·Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer, Renicus S. Hermanides, Arnoud W.J. van ‘t Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, (unknown), Folkert W. Asselbergs, Arend Mosterd, Jean‐Paul R. Herrman, Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder, Maarten J. Postma, Anthonius de Boer, Cornelis Boersma, Vera H.M. Deneer, Jurriën M. ten Berg	378
14	Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D 2019 ·Quality of Life Research ·Bustanul Arifin, (unknown), Antoinette D. I. van Asselt, Fredrick Dermawan Purba, Dyah Aryani Perwitasari, Jarir At Thobari, Qi Cao, Paul F. M. Krabbe, Maarten J. Postma	56
15	Sustainability of public finances: inclusion of unrelated medical cost only part of the story 2019 ·The European Journal of Health Economics ·Mark P. Connolly, (unknown), Aomesh Bhatt, Maarten J. Postma	1
16	The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders 2019 ·PLoS ONE ·(unknown), (unknown), Amr Makady, Maarten J. Postma, Wim Goettsch, Talitha Feenstra, Erik Buskens	6
17	Poster Abstracts 2013 ·Vox Sanguinis ·Nyashadzaishe Mafirakureva, Star Khoza, Marinus van Hulst, Maarten J. Postma, D Mvere, (unknown), (unknown)	4
18	Influenza vaccination of hospital healthcare staff from the perspective of the employer:a positive balance 2010 ·University of Groningen research database (University of Groningen / Centre for Information Technology) ·Eelko Hak, (unknown), Jan Wilschut, Maarten J. Postma	3
19	Possible role of cost-effectiveness of HPV vaccination within the decision context on inclusion of HPV in the country-specific national immunization programs 2010 ·Data Archiving and Networked Services (DANS) ·Mark H. Rozenbaum, (unknown), Maarten J. Postma	1
20	Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination 2008 ·Vaccine ·(unknown), (unknown), Mark H. Rozenbaum, Paul B. van den Berg, Eelko Hak, Erik Buskens, Jan Wilschut, Aloys C.M. Kroes, Maarten J. Postma	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact